---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-108359"
form_type: "8-K"
ticker: "OBIO"
cik: "0001814114"
company_name: "Orchestra BioMed Holdings, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:41:58.747417+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orchestra BioMed postpones Virtue SAB pivotal study to 2024 amid Terumo negotiations

## Summary
- Filed registration statement for resale of shares/warrants; not seeking additional capital.
- Negotiating with Terumo to restructure milestone payments and modify distribution agreement.
- Virtue ISR-US pivotal study initiation postponed to 2024 due to ongoing negotiations.
- If negotiations not satisfactory, clinical/commercial plans for Virtue SAB may be further affected.

## SEC filing metadata
- accession: 0001104659-23-108359
- form_type: 8-K
- ticker: OBIO
- cik: 0001814114
- company_name: Orchestra BioMed Holdings, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814114/000110465923108359/0001104659-23-108359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814114/000110465923108359/tm2328162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-108359
- JSON: https://secwatch.observer/filing/0001104659-23-108359.json
- Plain text: https://secwatch.observer/filing/0001104659-23-108359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.